The Treatment Choice
Today, Confidently
Protecting Your
Patients’ Tomorrow1-8

  1. Prins MH, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis J. 2013;11(1):21.
  2. Bauersachs R.M., Lensing A.W.A., Prins M.H. et al. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thrombosis J. 2014;12:25.
  3. Prins MH, et al. Lancet Haematol. 2014;1:e37–e46.
  4. Ageno W., Mantovani L.G., Haas S. et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol. 2016;3(1):e12–e21.
  5. Büller H.R., Prins M.H., Lensing A.W.A. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97.
  6. Xarelto (rivaroxaban) Summary of Product Characteristics as approved by the European Commission.
  7. Weitz JI, et al. N Engl J Med. 2017;376:1211–1222.
  8. Bauersachs R., Berkowitz S.D., Brenner B. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510.

For Prescribing Information please click here.

warningThis medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse events. Reports can also be sent directly to Bayer via this link. Both side effects or quality complaints can be reported to Bayer by email to

The information on this site is intended
for healthcare professionals based in Republic of Ireland only.

Are you a healthcare professional based in Republic of Ireland?

Sorry, the information on this website is intended for healthcare professionals based in Republic of Ireland only.